Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q2 2024 · 10-Q
Revenue$510.00K$510.00K+153.7% vs Q2 2023 Net Income-$17.87M-$17.87MN/M vs Q2 2023 EPS Diluted-$0.02-$0.02N/M vs Q2 2023 Operating Income-$17,464,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$16,718,000— Margins · derivedOperating margin-3424.3%+3330.4 pt vs Q2 2023
Net margin-3503.7%+3684.3 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end